Skip to main content
Advicenne logo

Advicenne — Investor Relations & Filings

Ticker · ALDVI ISIN · FR0013296746 LEI · 969500YT5VMEYAYODW34 PA Manufacturing
Open in API
Filings indexed 259 across all filing types
Latest filing 2021-12-07 Earnings Release
Country FR France
Listing PA ALDVI

About Advicenne

https://advicenne.com

Advicenne is a specialty pharmaceutical company dedicated to developing and commercializing treatments for rare renal diseases. The company focuses on addressing unmet medical needs in nephrology for both children and adults. Its lead product, Sibnayal®, is an approved treatment for distal Renal Tubular Acidosis (dRTA). Advicenne is committed to improving the lives of patients with rare kidney conditions by developing therapeutics, including pediatric-friendly formulations, suitable for patients of all ages.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Earnings Release Classification · 1% confidence The document is a press release dated December 7, 2021, announcing significant progress in the commercialization and distribution of the drug Sibnayal™ in Europe, including pricing agreements in the UK and new distribution partnerships covering 25% of European patients. This type of announcement, detailing business developments, partnerships, and initial market access milestones (like pricing negotiations and distribution deals), is characteristic of an Earnings Release (ER) or a general corporate update. Since it focuses on operational and commercial achievements rather than just financial figures (which would lean towards ER) or a formal regulatory filing, it fits best as an announcement of business progress. However, given the options, it is a high-level announcement of commercial progress and partnership execution, which often accompanies or precedes formal earnings reports. It is not a full financial report (10-K or IR), a transcript (CT), or a specific regulatory filing like DIRS or DIV. It is a press release detailing significant business updates. In the context of the provided definitions, this is a general corporate announcement about commercial strategy and execution, which is often categorized under Earnings Release (ER) if it relates to period performance, or sometimes as Regulatory Filing (RNS) if it's a broad market update. Since it details commercial progress and partnership terms, it functions as an announcement of operational achievements. Given the structure and content (announcing commercial milestones), it most closely aligns with an Earnings Release (ER) which often includes operational highlights, or a general announcement. Since it is not a formal financial statement, but a press release detailing commercial progress, 'ER' (Earnings Release - initial announcement of periodical financial results/highlights) is a strong candidate, as commercial progress is a key highlight. Alternatively, if it were purely non-financial news, RNS would apply. Given the context of pharmaceutical commercialization, this is a key business update often released around reporting periods. I will classify it as an Earnings Release (ER) as it provides key commercial highlights that drive future earnings, even if it's not the formal financial table release itself, or RNS as a general announcement. Given the focus on commercial execution and pricing, ER is slightly more appropriate than the generic RNS, but since it's not explicitly stating quarterly/periodical results, RNS (Regulatory Filings - general regulatory announcements and fallback) is the safest fit for a non-standard announcement type, though ER captures the spirit of a business update. Let's re-evaluate: It's a press release announcing commercial progress, not a formal financial report. This is a classic 'Earnings Release' type announcement, even if it lacks the full P&L. I will select ER. FY 2021
2021-12-07 French
Modalités de mise à disposition de document de référence ou de ses actualisations
Report Publication Announcement Classification · 1% confidence The document is a press release titled "Advicenne annonce la mise à disposition de son document d'enregistrement universel" (Advicenne announces the availability of its universal registration document). It explicitly states that the Universal Registration Document (URD) has been filed with the AMF (Autorité des Marchés Financiers) and is available for public consultation on the company's and AMF's websites. The document itself is short (3458 characters) and serves to announce the publication of other, larger reports (2020 annual accounts, 2021 semi-annual accounts, and a share repurchase program description). According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement stating that a report has been published or made available points to a Report Publication Announcement (RPA).
2021-12-06 French
Document d'Enregistrement Universel FY20
Regulatory Filings Classification · 1% confidence The document text is extremely short and states: "**Document supprimé à la demande de l'émetteur**" (Document deleted at the request of the issuer). This is not a standard financial report, an earnings release, or a specific regulatory filing content. It is an administrative notice regarding the removal of a document. Since there is no specific category for 'Document Deletion Notice,' and it is a general regulatory/administrative action, the most appropriate fallback category is 'Regulatory Filings' (RNS), as it represents an official communication to the market about a filing status change, even if the content is nullified.
2021-12-06 French
Inside Information / Other news releases
Delisting Announcement Classification · 1% confidence The document is a press release dated December 3, 2021, announcing the Board of Directors' decision to propose the transfer of Advicenne's share listing from the regulated market of Euronext Paris to the Euronext Growth Paris market, and the concomitant delisting from Euronext Brussels. This action directly relates to the company's capital structure and listing venue, which falls under financing activities or capital structure changes. While it involves delisting (DLST) and share structure (SHA), the core announcement is about a strategic change in market listing, which is best categorized under Capital/Financing Update (CAP) as it details the rationale (market suitability, free float) and the process for this significant capital market event. It is not a formal regulatory filing like a 10-K or an ER, but a strategic corporate action announcement.
2021-12-03 English
Informations privilégiées / Autres communiqués
Delisting Announcement Classification · 1% confidence The document is a press release dated December 3, 2021, announcing the company's intention to transfer its stock listing from the regulated market of Euronext Paris (Compartment C) to the multilateral trading facility Euronext Growth Paris, and simultaneously delist from Euronext Brussels. This involves proposing the transfer to an upcoming Ordinary General Meeting of Shareholders (scheduled for January 21, 2022). The content focuses on the corporate action (transfer/delisting), the rationale, and the implications for financial reporting and shareholder protection. Since the core subject is a significant corporate action related to market listing and structure, and it is being announced via a press release detailing the plan and timeline, it fits best under Capital/Financing Update (CAP) as it directly concerns the capital structure/listing venue, or potentially Regulatory Filings (RNS) as a general announcement. However, given the specific nature of changing listing venues and the associated shareholder vote, 'CAP' (Capital/Financing Update) is a strong candidate. It is not a report itself (like 10-K or IR), nor is it solely a proxy solicitation (PSI) or a dividend notice (DIV). It is an announcement of a major structural/financing decision requiring shareholder approval. I will classify it as CAP due to the focus on the change in listing venue and capital market structure.
2021-12-03 French
Inside Information / News release on accounts, results
Earnings Release Classification · 1% confidence The document is an announcement of half-year financial results for Advicenne. While it contains summary financial tables (Income Statement, Balance Sheet, Cash Flow), it is structured as a press release (indicated by the dateline, contact information, and forward-looking statements disclaimer). Although it provides substantive financial data, it functions as an Earnings Release (ER) rather than a full Interim Report (IR), as it is a summary announcement intended for public dissemination of key highlights. H1 2021
2021-09-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.